Place · Level 3
Postmenopausal Health
月经停了 12 个月之后的低雌激素长期态· 骨量加速流失 → 骨松窗口 · 心血管风险上行 · GSM 不自愈 · 体成分代谢转变 · MHT 时机假说的诚实复盘 · 该监测什么 · 与医师共同决策
Last updated
Story path
- 1After the transition · the durable low-estrogen stateAfter the transition · the durable low-estrogen state
- 2Bone · the accelerated-loss window → osteoporosis riskBone · the accelerated-loss window → osteoporosis risk
- 3Cardiovascular · risk rises once estrogen's protection is goneCardiovascular · risk rises once estrogen's protection is gone
- 4GSM + body composition · the parts that don't self-resolveGSM + body composition · the parts that don't self-resolve
- 5MHT · the honest post-WHI reappraisal + timing hypothesisMHT · the honest post-WHI reappraisal + timing hypothesis
- 6What to actually monitor + atlas loopWhat to actually monitor + atlas loop
Chapter 1
After the transition · the durable low-estrogen state
After the transition · the durable low-estrogen state
Perimenopause (dive to perimenopause) is about 'the transition' — that 4-10 year stretch of wildly fluctuating estrogen and waxing-and-waning hot flashes. This island starts after that: once you've gone 12 consecutive months without a period, you enter postmenopause — a stable, durable low-estrogen state that will last roughly a third of the rest of your life.
Not a 'symptom phase' — a 'new baseline'
Perimenopause is about fluctuation; postmenopause is about stabilizing at a low levelThis means: among the symptoms people 'wait out,' some genuinely fade naturally (most hot flashes), but others do not self-resolve and instead persist or progress with the low-estrogen state (bone loss, GSM)This is the key division of labor with perimenopause: we don't repeat the transition story; we tell 'how each body system resets after estrogen is durably gone'
What estrogen was actually protecting (now departed)
Before menopause, estrogen is a system-wide protective hormone, not just reproductive:
Bone: suppresses osteoclasts (receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone./OPG balance, dive to osteoporosis) → resorption accelerates after it departsVessels: improves endothelial function, modulates lipids → cardiovascular risk rises after it departsUrogenital tissue: maintains the thickness and elasticity of vaginal / urethral epithelium → GSM after it departsFat distribution and metabolism: maintains subcutaneous (pear) distribution, improves insulin sensitivity → visceral fat rises after it departsTemperature and sleep centers: sets the temperature threshold, shapes sleep architecture
The stance of this island
Postmenopause is not 'the beginning of decline,' nor should it be fear-mongered. It is a life stage you can actively manage — some systems' risks do rise, but each has clear monitoring metrics and modifiable levers. This site does not replace a physician; it helps you understand the mechanism and bring judgment to shared decisions with your clinician.
Below, system by system: bone → cardiovascular → GSM → body composition/metabolism → the MHT decision → what to actually monitor.
Not a 'symptom phase' — a 'new baseline'
Perimenopause is about fluctuation; postmenopause is about stabilizing at a low levelThis means: among the symptoms people 'wait out,' some genuinely fade naturally (most hot flashes), but others do not self-resolve and instead persist or progress with the low-estrogen state (bone loss, GSM)This is the key division of labor with perimenopause: we don't repeat the transition story; we tell 'how each body system resets after estrogen is durably gone'
What estrogen was actually protecting (now departed)
Before menopause, estrogen is a system-wide protective hormone, not just reproductive:
Bone: suppresses osteoclasts (receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone./OPG balance, dive to osteoporosis) → resorption accelerates after it departsVessels: improves endothelial function, modulates lipids → cardiovascular risk rises after it departsUrogenital tissue: maintains the thickness and elasticity of vaginal / urethral epithelium → GSM after it departsFat distribution and metabolism: maintains subcutaneous (pear) distribution, improves insulin sensitivity → visceral fat rises after it departsTemperature and sleep centers: sets the temperature threshold, shapes sleep architecture
The stance of this island
Postmenopause is not 'the beginning of decline,' nor should it be fear-mongered. It is a life stage you can actively manage — some systems' risks do rise, but each has clear monitoring metrics and modifiable levers. This site does not replace a physician; it helps you understand the mechanism and bring judgment to shared decisions with your clinician.
Below, system by system: bone → cardiovascular → GSM → body composition/metabolism → the MHT decision → what to actually monitor.
围绝经期与绝经后 · 波动和低位不是一回事
前面的围绝经期 (perimenopause) 讲的是过渡——那段 4-10 年、雌激素剧烈波动、潮热起伏的阶段 (dive 到 perimenopause); 这一岛从那之后开始。不是症状期, 是新基线
围绝经期的核心是波动; 绝经后的核心是稳定在低位这意味着: 那些等忍过去就好的症状里, 有一部分确实会自然减弱 (比如多数潮热), 但另一部分不会自愈, 而是随低雌激素态长期存在甚至进展 (比如骨流失、GSM)这是本岛与 perimenopause 最重要的分工: 我们不重复过渡期的故事, 而是讲雌激素长期缺位后, 身体各系统怎么重新设定
为什么波动更难受, 低位却更危险
潮热这类症状, 身体反应的是变化的速率: 激素一路往下掉的过程中, 大脑的调温中枢一次次重新校准, 于是有起有伏。等它落到底、不再动了, 校准这件事慢慢完成, 多数人的潮热因此自然淡掉 —— 这就是熬过去真的成立的那一半。
而骨、血管、泌尿生殖组织认的不是速率, 是水平。它们每天都要靠雌激素维持一个日常的修补速度: 拆掉多少补回多少、管壁松紧调到多少、上皮多久换一茬。水平掉下去且不再回来, 这些组织就停在一个更慢的修补速度上, 天天如此。所以它们不会熬过去, 只会累积 —— 这也是为什么本岛把重点放在它们身上。
这一岛的态度
绝经后不是衰退的开始, 也不该被恐吓。它是一个可以主动管理的人生阶段 —— 有些系统的风险确实上升, 但每一项都有明确的监测指标和可干预的杠杆。本站不替代医师, 而是帮你理解机制, 带着判断力去和你的医师共同决策。
机制 · 一个激素凭什么能同时管这么多系统
读到这里很容易冒出一个疑问: 骨头、血管、体温、脂肪, 这四件事看起来八竿子打不着, 凭什么一个激素同时管得着?答案在于雌激素干活的方式和大多数激素不一样。
胰岛素、肾上腺素这类激素是水溶性的, 进不了细胞, 只能停在细胞表面的受体上敲门, 然后靠细胞内部的一串接力把消息传进去。它们的效果快, 但也短。雌激素是脂溶性的小分子, 细胞膜那层油脂对它几乎不设防, 它直接穿过去, 在细胞内部找到自己的受体。这一对搭档接着走进细胞核, 停靠在 DNA 上特定的位置, 改变的是哪些基因被抄写成蛋白质、抄写多快。
换句话说, 雌激素不是在下达一条指令, 而是在调整一批设置。而带着这种受体的细胞遍布全身: 成骨细胞和破骨细胞、血管内皮、下丘脑的调温神经元、脂肪细胞、阴道上皮 —— 它们各自被调整的设置项不同, 所以同一个激素在不同地方做的事看起来毫不相干。
这就解释了两件事
为什么撤退的下游这么散: 不是雌激素顺便影响了很多器官, 而是这些器官原本就把自己的一部分日常参数托管给了同一个信号。信号撤走, 每个器官各自回落到自己的默认值 —— 表现自然千差万别。为什么一瓶补剂搞定绝经不成立: 要复制的不是一个反应, 是分布在几十种细胞里的一批设置。任何单一营养素都只能补上其中某一条链的原料 (比如钙和维生素 D 补的是骨的原料), 补不了发号施令的那一层。这不是说营养没用 —— 而是说, 该由营养解决的和该由激素或药物解决的, 本来就不是同一件事。
顺带一提: 上面这个设置被改变的特性, 也解释了为什么激素治疗的效果不是吃下去就有 —— 基因抄写、蛋白质合成、组织翻新都要时间, 所以无论是全身还是局部用药, 组织层面的变化通常要几周才看得出来。
Chapter 2
Bone · the accelerated-loss window → osteoporosis risk
Bone · the accelerated-loss window → osteoporosis risk
The single most important sentence about postmenopausal bone health: bone loss is not 'aging' that starts at 70 — it bursts concentratedly in the years around the final menstrual period (FMP), then settles into a slower steady loss. Understanding this acceleration window is key to deciding when to screen and when to intervene.
Mechanism: estrogen withdrawal → osteoclasts off the leash (dive to osteoporosis for the receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone./OPG L4)
With normal estrogen: ↑ OPG (decoy receptor) + ↓ RANKL → osteoclasts held down, formation ≥ resorptionWith estrogen withdrawal: RANKL ↑ → osteoclasts activated → resorption exceeds formation → net loss
Quantifying the acceleration window (Greendale et al. 2012, SWAN cohort, *JBMR*)
This multi-ethnic cohort tracked bone density for 5 years before and after the FMP:
Bone loss begins accelerating about 1 year before the final menstrual period and continues to about 2-3 years after the FMPDuring this 'transmenopause' window, lumbar spine and femoral neck bone density fall about 2% per year — markedly faster than before or afterIn other words: the years around menopause are the fastest stretch of bone loss in a lifetime — it is not gradual
Why this deserves serious attention
Fracture risk (especially vertebral and hip) rises exponentially after 65, but the bone capital was rapidly drained during that window around 50Hip fracture in older women is significantly associated with disability and mortality — it is not just 'a fall'This is the core of the atlas's repeated 'don't miss this decade': the prevention window comes first, the consequences later
How to know your bone status (screening) (USPSTF 2025)
The US Preventive Services Task Force 2025 update recommends: routine DXA screening for osteoporosis in women 65 and older (B recommendation)For postmenopausal women under 65 with risk factors (low body weight / parental hip fracture / smoking / excess alcohol / early menopause / long-term glucocorticoids), use clinical risk assessment (e.g. FRAX) to decide on earlier screeningDXA is the preferred measurement
Practical (the basics, for everyone)
Calcium 1,000-1,200 mg/day, food first (dairy / yogurt / tofu / small fish with bones / greens); supplements only fill the gapVitamin D kept sufficient (dive to vitamin-d): bone calcium deposition needs itWeight-bearing + strength training 2-3×/week — more important for maintaining bone density than any single supplementQuit smoking, limit alcohol — both directly accelerate bone loss
Drug tiering with FRAX decisions and the bisphosphonate / denosumab details are covered fully in the osteoporosis island (dive to osteoporosis) — with complete T-score interpretation, FRAX thresholds, and the drug ladder. This island's job is to make clear: the acceleration window is around menopause, so the screening and intervention decisions must move earlier too.
Mechanism: estrogen withdrawal → osteoclasts off the leash (dive to osteoporosis for the receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone./OPG L4)
With normal estrogen: ↑ OPG (decoy receptor) + ↓ RANKL → osteoclasts held down, formation ≥ resorptionWith estrogen withdrawal: RANKL ↑ → osteoclasts activated → resorption exceeds formation → net loss
Quantifying the acceleration window (Greendale et al. 2012, SWAN cohort, *JBMR*)
This multi-ethnic cohort tracked bone density for 5 years before and after the FMP:
Bone loss begins accelerating about 1 year before the final menstrual period and continues to about 2-3 years after the FMPDuring this 'transmenopause' window, lumbar spine and femoral neck bone density fall about 2% per year — markedly faster than before or afterIn other words: the years around menopause are the fastest stretch of bone loss in a lifetime — it is not gradual
Why this deserves serious attention
Fracture risk (especially vertebral and hip) rises exponentially after 65, but the bone capital was rapidly drained during that window around 50Hip fracture in older women is significantly associated with disability and mortality — it is not just 'a fall'This is the core of the atlas's repeated 'don't miss this decade': the prevention window comes first, the consequences later
How to know your bone status (screening) (USPSTF 2025)
The US Preventive Services Task Force 2025 update recommends: routine DXA screening for osteoporosis in women 65 and older (B recommendation)For postmenopausal women under 65 with risk factors (low body weight / parental hip fracture / smoking / excess alcohol / early menopause / long-term glucocorticoids), use clinical risk assessment (e.g. FRAX) to decide on earlier screeningDXA is the preferred measurement
Practical (the basics, for everyone)
Calcium 1,000-1,200 mg/day, food first (dairy / yogurt / tofu / small fish with bones / greens); supplements only fill the gapVitamin D kept sufficient (dive to vitamin-d): bone calcium deposition needs itWeight-bearing + strength training 2-3×/week — more important for maintaining bone density than any single supplementQuit smoking, limit alcohol — both directly accelerate bone loss
Drug tiering with FRAX decisions and the bisphosphonate / denosumab details are covered fully in the osteoporosis island (dive to osteoporosis) — with complete T-score interpretation, FRAX thresholds, and the drug ladder. This island's job is to make clear: the acceleration window is around menopause, so the screening and intervention decisions must move earlier too.
机制 · 开拆的信号是怎么被松开的
(dive 到 osteoporosis 看 receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone./OPG 的 L4 动画)骨面上住着一群等着上岗的破骨前体细胞。负责建骨的成骨细胞会往它们身上送一个开拆的信号分子 (RANKL): 它停靠在前体细胞表面的受体上, 几个前体细胞就融合成一个多核的大细胞 —— 破骨细胞。它贴到骨面上, 用起了褶皱的细胞膜把一小块骨面像吸盘一样封起来, 然后往这个封闭的小空间里泵酸和蛋白酶: 酸溶掉矿物质, 蛋白酶剪断胶原纤维。一个坑就这么挖出来了。
成骨细胞同时还会送出另一个分子 (OPG)。它长得像 RANKL 的受体, 却不连着任何细胞 —— RANKL 一头撞上它就被抓住, 再也到不了真受体那里。所以 OPG 是诱饵, 是刹车片。
雌激素做的事, 就是同时踩两边: 抬高 OPG, 压低 RANKL。
雌激素正常时: OPG 多、RANKL 少 → 破骨细胞招不满人、活不长 → 建的速度追得上拆的速度雌激素撤离: RANKL 相对变多 → 破骨细胞被大量激活、还活得更久 → 骨吸收超过骨形成 → 净流失
所以会怎样: 坑一个接一个挖出来, 填坑的队伍来不及跟上, 最先被打断的是骨小梁 —— 骨头内部那些像海绵一样互相搭着的细横梁。横梁一旦被拆断, 剩下的横梁再粗也接不回原来的结构。这正是为什么骨密度只掉一点点, 骨折风险却能涨很多: 丢掉的不只是重量, 还有结构。
能自己往下推的一件事: 凡是让 RANKL 相对变多的处境, 都会重演同一条链 —— 长期用糖皮质激素、长期卧床不动、雌激素过早消失 (早绝经、卵巢切除)。反过来看, 能让建的那一边加速的输入非常有限, 负重和力量训练是其中最可靠的一个。这就是为什么在这一岛的实操清单里, 它排在任何补剂前面。
数字 · 加速窗口到底有多快
加速窗口的量化 (Greendale et al. 2012, SWAN 队列, *JBMR*)这项多族裔队列追踪了女性 FMP 前后各 5 年的骨密度:
骨量流失在末次月经前约 1 年开始加速, 持续到 FMP 后约 2-3 年这个跨经期 (transmenopause)窗口里, 腰椎和股骨颈骨密度每年流失约 2% 左右, 显著快于此前此后也就是说: 绝经前后这几年, 是一生中骨流失最快的一段 —— 不是慢慢来的
这里有一个反直觉的地方: FMP 是末次月经 (final menstrual period), 而它要等到之后连续十二个月不再来月经, 才被回过头认定为末次。也就是说, 加速窗口只能事后看清 —— 你正处在窗口里的时候, 它还没有名字。这不是学术上的挑剔, 而是这一幕最实际的一条推论: 别等确认了再开始。负重训练、钙和维生素 D、戒烟限酒, 这些在窗口前就该到位, 而且它们本来也没有需要等待确认的理由。
为什么这件事值得严肃对待
骨折风险 (尤其椎体、髋部) 在 65 岁后指数上升, 但骨本是在 50 岁前后那个窗口被快速掏空的髋部骨折在老年女性中与残疾、死亡率显著相关 —— 它不是摔一跤那么简单这是 atlas 反复强调这十年别错过的核心: 预防的窗口在前, 后果在后
临床 · 什么时候查, 日常怎么护
怎么知道自己的骨况 (筛查) (USPSTF 2025)美国预防服务工作组 2025 更新建议: 65 岁及以上女性常规用 DXA 筛查骨质疏松 (B 级推荐)65 岁以下的绝经后女性, 若有风险因素 (低体重、父母髋骨折史、吸烟、过量饮酒、早绝经、长期糖皮质激素), 用临床风险评估 (如 FRAX) 决定是否提前筛查DXA 是首选测量方法
实操 (基础, 人人适用)
钙 1000-1200 mg/天, 食物优先 (奶、酸奶、豆腐、带骨小鱼、绿叶), 补剂只补差额维生素 D 维持充足 (dive 到 vitamin-d): 骨钙沉积需要它负重 + 力量训练 2-3 次/周 —— 对维持骨密度比任何单一补剂都重要戒烟限酒 —— 两者都直接加速骨流失
为什么必须是负重, 不是随便动一动
骨细胞埋在骨基质里, 看不见也摸不着外界, 它判断要不要加固靠的是形变。肌肉拉扯骨头、地面的反作用力压过骨干, 骨里那些极细的孔道中的液体就被挤着流动一下; 埋在里面的骨细胞感到这股冲刷, 就发信号让建的那一边多干活。
所以同样是运动, 回报差别很大: 游泳和骑车对心肺极好, 但水的浮力和车座分担了体重, 骨头没挨到那股压过去的力, 对骨密度的回报就小得多。走路、慢跑、上下台阶、负重深蹲, 才是骨细胞听得懂的语言。
这条也解释了长期卧床为什么掉骨最快: 不是躺着有什么毒性, 而是没有形变输入, 骨细胞收到的消息始终是这里用不上这么多骨头。
药物分层与 FRAX 决策、双膦酸盐、地舒单抗的细节 在 osteoporosis 岛讲透 (dive 到 osteoporosis) —— 那里有完整的 T-score 解读、FRAX 阈值和药物阶梯。本岛的任务是让你明白: 加速窗口在绝经前后, 所以筛查和干预的决策也要往前提。
Chapter 3
Cardiovascular · risk rises once estrogen's protection is gone
Cardiovascular · risk rises once estrogen's protection is gone
Before menopause, women's cardiovascular disease rates are clearly lower than same-age men's — estrogen's vascular protection is one major reason. After menopause that protection departs, and women's cardiovascular risk begins to rise, gradually catching up to men's over the following decade-plus. This is not the vague 'old vessels go bad' — it is a transition with a clear mechanism and timing.
What estrogen does in vessels (reversed once it departs)
Promotes endothelial nitric oxide (nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens.) release → maintains vasodilation and elasticityModulates lipids: helps keep LDL lower, HDL higherAnti-inflammatory, antioxidant effects on the vessel wallAfter it departs: endothelial function declines, the lipid profile worsens, arterial stiffness increases
The menopause transition is a cardiovascular-risk 'acceleration point' (El Khoudary et al. 2020, AHA scientific statement)
The American Heart Association's 2020 scientific statement systematically reviewed the evidence, with a core conclusion:
A growing body of literature supports an acceleration of cardiovascular risk during the menopause transition — not merely a 'linear increase with age'Adverse changes observed during the transition: rising LDL / total cholesterol, increased visceral fat, progression of vascular structure (carotid intima-media thickness), and worsening lipid-metabolism and blood-pressure trendsThe statement emphasizes that the transition is a critical window for early prevention — women's cardiovascular health should be monitored and managed in midlife, not after an event
What this means for you (modifiable, no need to panic)
The postmenopausal rise in cardiovascular risk is real but highly modifiable — it layers on top of all the traditional risk factors, which you can manage:
Blood pressure: measure regularly, keep it at goal (dive to hypertension)Lipids: monitor LDL, discuss statins etc. with your clinician if warranted (dive to cardiovascular)Glucose / metabolism: watch waist circumference and insulin resistance (detailed next)Lifestyle: Mediterranean / DASH diet, regular aerobic + strength work, no smoking, limited alcohol — these pay off more after menopause, because you've lost estrogen's 'free protection'
A one-line preview on MHT and the heart
You may have heard 'estrogen protects the heart' — this is the very heart of the MHT 'timing hypothesis' controversy. The short conclusion: started in the right timing window (early menopause, before 60), MHT is neutral or even slightly favorable for cardiovascular outcomes; but a late start (years after menopause) should not be used 'to protect the heart.' The full WHI re-appraisal and the KEEPS / ELITE RCT triangulation are covered in the MHT decision scene later.
Bottom line: the postmenopausal rise in cardiovascular risk is a transition with a clear mechanism, but it lands on the traditional risk factors you can manage. Managing blood pressure, lipids, metabolism, and lifestyle is closer to the mechanism than any 'heart-protecting supplement.'
What estrogen does in vessels (reversed once it departs)
Promotes endothelial nitric oxide (nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens.) release → maintains vasodilation and elasticityModulates lipids: helps keep LDL lower, HDL higherAnti-inflammatory, antioxidant effects on the vessel wallAfter it departs: endothelial function declines, the lipid profile worsens, arterial stiffness increases
The menopause transition is a cardiovascular-risk 'acceleration point' (El Khoudary et al. 2020, AHA scientific statement)
The American Heart Association's 2020 scientific statement systematically reviewed the evidence, with a core conclusion:
A growing body of literature supports an acceleration of cardiovascular risk during the menopause transition — not merely a 'linear increase with age'Adverse changes observed during the transition: rising LDL / total cholesterol, increased visceral fat, progression of vascular structure (carotid intima-media thickness), and worsening lipid-metabolism and blood-pressure trendsThe statement emphasizes that the transition is a critical window for early prevention — women's cardiovascular health should be monitored and managed in midlife, not after an event
What this means for you (modifiable, no need to panic)
The postmenopausal rise in cardiovascular risk is real but highly modifiable — it layers on top of all the traditional risk factors, which you can manage:
Blood pressure: measure regularly, keep it at goal (dive to hypertension)Lipids: monitor LDL, discuss statins etc. with your clinician if warranted (dive to cardiovascular)Glucose / metabolism: watch waist circumference and insulin resistance (detailed next)Lifestyle: Mediterranean / DASH diet, regular aerobic + strength work, no smoking, limited alcohol — these pay off more after menopause, because you've lost estrogen's 'free protection'
A one-line preview on MHT and the heart
You may have heard 'estrogen protects the heart' — this is the very heart of the MHT 'timing hypothesis' controversy. The short conclusion: started in the right timing window (early menopause, before 60), MHT is neutral or even slightly favorable for cardiovascular outcomes; but a late start (years after menopause) should not be used 'to protect the heart.' The full WHI re-appraisal and the KEEPS / ELITE RCT triangulation are covered in the MHT decision scene later.
Bottom line: the postmenopausal rise in cardiovascular risk is a transition with a clear mechanism, but it lands on the traditional risk factors you can manage. Managing blood pressure, lipids, metabolism, and lifestyle is closer to the mechanism than any 'heart-protecting supplement.'
机制 · 那层只有一个细胞厚的膜
雌激素在血管里做的事 (退场后逆转)促进血管内皮释放一氧化氮 (NO) → 维持血管舒张与弹性调节血脂: 帮助维持较低 LDL、较高 HDL抗炎、抗氧化的血管壁效应退场后: 内皮功能下降、血脂谱变差、血管僵硬度增加
把第一条完整展开
雌激素结合到内皮细胞的受体上之后, 会让细胞里那台负责造 nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. 的酶 (一氧化氮合酶) 更活跃。NO 是一种气体, 造出来就四下扩散, 几秒之内穿过内皮、进到下面那圈平滑肌里, 让平滑肌松开手。血管这才在你爬楼梯、天冷缩起来、情绪一激动的时候跟得上需求。
NO 少了, 三件事同时变差:
反应慢: 血流一大, 血管本该顺势撑开; 现在撑得慢、撑得少。临床上量的血流介导舒张, 量的就是这一项变硬: 平滑肌长期不松, 加上管壁结构改变, 整根血管的顺应性下降, 收缩压更容易被推高更容易起斑块: NO 本来还压着白细胞往管壁上贴、压着平滑肌乱长; 它一少, 被氧化的 LDL 更容易钻进内皮下面, 被巨噬细胞吞成泡沫细胞 —— 这正是动脉粥样硬化的起点 (dive 到 cardiovascular)
所以会怎样: 这不是某天血管突然坏掉, 而是同一根血管每天少了一点弹性储备。它也解释了一件常被误读的事 —— 为什么绝经后血压、血脂、血管硬度的数字会一起往不好的方向漂。它们不是三个独立的坏消息, 而是同一层细胞状态改变之后的三个读数。
数字 · 过渡期是加速点, 以及该管什么
绝经过渡是心血管风险的加速点 (El Khoudary et al. 2020, AHA 科学声明)美国心脏协会 2020 年的科学声明系统梳理了证据, 核心结论:
越来越多的研究支持: 心血管风险在绝经过渡期出现加速, 而不只是随年龄线性增加过渡期内可观察到的不利变化: LDL / 总胆固醇上升、内脏脂肪增加、血管结构 (颈动脉内膜中层厚度) 进展、血脂代谢和血压趋势变差声明强调: 绝经过渡是早期预防的关键窗口 —— 应在中年就开始监测和管理女性心血管健康, 而不是等到事件发生
这对你意味着什么 (可干预, 不必恐慌)
血压: 定期测, 维持达标 (dive 到 hypertension)血脂: 监测 LDL, 必要时与医师讨论他汀等 (dive 到 cardiovascular)血糖、代谢: 关注腰围与胰岛素抵抗 (下一幕详)生活方式: 地中海 / DASH 饮食、规律有氧 + 力量、戒烟、限酒 —— 这些在绝经后回报更高, 因为你失去了雌激素这层免费保护
为什么运动在这里格外对位
每一次心跳把血推过血管, 血流刮擦内皮表面, 产生的那股切向的摩擦力是内皮开工造 nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. 的主要触发器之一。规律有氧, 等于每天给这条通路加班 —— 它补的恰好是雌激素退场后少掉的那一环。
这也是为什么在血管这件事上, 练比补更接近机制: 补剂送的是原料, 而内皮缺的不是原料, 是开工的信号。
预告 · MHT 与心脏, 以及那个时机窗
你可能听过雌激素能护心 —— 这正是 MHT 时机假说争议的核心。简短结论: 在合适的时机窗 (绝经早期、60 岁前) 开始 MHT, 对心血管是中性甚至偏有利的; 但晚启动 (绝经多年后) 不应为了护心而用。 完整的 WHI 复盘、KEEPS / ELITE 的 RCT 三角验证, 在后面的 MHT 决策场景讲透。为什么可能存在这样一个窗口 (机制上的推想, 不是定论)
上一页说过, 雌激素的血管获益走的是内皮那条路 —— 那需要内皮还在工作。刚绝经时血管壁大体还健康, 把雌激素补回来相当于把产 nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. 的那条线重新接上; 而绝经很多年后, 管壁上往往已经有了成熟斑块, 此时药物作用的对象已经不是一层健康内皮了。
必须说清的是: 这只是假说给出的解释, 不是被直接证明的因果。年龄和绝经年限没办法随机分配, 所以严格意义上只检验时机的随机试验并不存在。现有支持来自两类证据: 按年龄事后分层的再分析 (分层是事后做的, 强度低于原始的随机比较), 以及以血管影像为终点的试验 (终点是替代指标, 不是心梗或死亡本身)。
底线: 绝经后心血管风险上行是机制清楚的转变, 但它落在你能管理的传统危险因素上。把血压、血脂、代谢、生活方式管好, 比纠结任何护心补剂都更接近机制。
Chapter 4
GSM + body composition · the parts that don't self-resolve
GSM + body composition · the parts that don't self-resolve
Postmenopause brings two classes of change whose defining trait is that they don't self-resolve over time and instead progress — which is exactly why 'just wait it out' so often delays them.
1 · Genitourinary syndrome of menopause (GSM) (dive to perimenopause for the full treatment ladder)
GSM (formerly 'vulvovaginal atrophy') covers the whole urogenital system's response to low estrogen: vaginal dryness, burning, painful intercourse, recurrent UTIs, urinary urgency and frequencyThe key distinction from hot flashes: hot flashes mostly fade over the years after the transition; GSM persists and progresses without treatment — the longer you wait, the harder to treatMechanism: thinning vaginal / urethral epithelium, declining collagen and elastin, rising vaginal pH, altered microbiomeSeverely undertreated: due to embarrassment, the 'it's just aging' misconception, and not knowing treatment existsCore point (detailed in the perimenopause GSM scene): local low-dose vaginal estrogen leaves plasma levels essentially unchanged, has a risk profile entirely different from systemic MHT, and is not bound by systemic MHT's 'within 10 years / before 60' initiation window; pair it with pelvic-floor physical therapyHow effective? The guideline gives a judgement, not a percentage. NAMS 2020 states that low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy and ospemifene are effective treatments for moderate-to-severe GSM. It asserts effectiveness and gives no efficacy rate — so the takeaway is 'this is treatable, and enduring it is a choice', not a number⚠️ One group must take a different route: women with a history of breast cancer or an estrogen-sensitive tumour. The same NAMS 2020 statement says there are insufficient data to confirm the safety of vaginal estrogen, vaginal DHEA or ospemifene in women with breast cancer, and that GSM management should follow the woman's needs and her oncologist's recommendation. Local dosing sidesteps systemic MHT's *timing window* — it does not sidestep the contraindication. Non-hormonal vaginal moisturisers, lubricants and pelvic-floor physical therapy remain a safe first step
2 · Body composition and metabolic shift
Estrogen maintains subcutaneous (pear) fat distribution; once it departs, fat redistributes to the abdomen / viscera (shifting toward an 'apple shape')Rising visceral fat → rising insulin resistance → metabolic syndrome, type 2 diabetes, fatty liver, and cardiovascular risk all rise with it (dive to type-2-diabetes / nafld / cardiovascular)A common confusion: 'I haven't changed what I eat or how I move, but my weight went up and my waist clearly thickened' — this part is genuinely endocrine-driven, not a 'willpower problem'Meanwhile, muscle mass declines with age (sarcopenia, dive to sarcopenia); layered on rising fat = 'sarcopenic obesity,' invisible on the scale but most harmful to function
How to handle the body-composition shift (mechanism-matched levers)
Strength training (the highest-ROI single intervention): maintains muscle → maintains basal metabolism + insulin sensitivity + fall prevention, 2-3×/weekProtein 1.2-1.6 g/kg/day: the floor is the PROT-AGE expert group's recommendation for older adults who exercise (≥ 1.2 g/kg/day); the ceiling comes from Morton 2018's meta-regression, where resistance-training gains plateau around 1.6 g/kg/day and adding more buys nothing. Postmenopausal protein needs are routinely underestimated, and breakfast is especially often short (dive to sarcopenia)Watch waist, not just weight: visceral fat is the core risk, and the scale will mislead youMediterranean / DASH diet + regular aerobic work: directly offset visceral fat and metabolic risk
Marketing-trap reminder
'Menopause-specific' big-bottle supplement blends, 'natural hormone balance' / 'detox anti-aging' formulas: usually black cohosh + soy isoflavones + a vitamin mix, with weak evidence on hard bone / cardiovascular / GSM endpoints'Compounded BHRT (bioidentical hormones)' from compounding pharmacies: NAMS explicitly warns against it — standard-formulation MHT is itself bioidentical and properly regulated (detailed next)
Bottom line: postmenopause has things that self-resolve (most hot flashes) and things that don't (GSM, bone loss, the body-composition shift). Identifying and treating early the parts that don't self-resolve is this island's most practical lesson. GSM is safe and treatable — don't endure it; the body-composition shift responds to strength training + protein + waist monitoring, not supplements.
1 · Genitourinary syndrome of menopause (GSM) (dive to perimenopause for the full treatment ladder)
GSM (formerly 'vulvovaginal atrophy') covers the whole urogenital system's response to low estrogen: vaginal dryness, burning, painful intercourse, recurrent UTIs, urinary urgency and frequencyThe key distinction from hot flashes: hot flashes mostly fade over the years after the transition; GSM persists and progresses without treatment — the longer you wait, the harder to treatMechanism: thinning vaginal / urethral epithelium, declining collagen and elastin, rising vaginal pH, altered microbiomeSeverely undertreated: due to embarrassment, the 'it's just aging' misconception, and not knowing treatment existsCore point (detailed in the perimenopause GSM scene): local low-dose vaginal estrogen leaves plasma levels essentially unchanged, has a risk profile entirely different from systemic MHT, and is not bound by systemic MHT's 'within 10 years / before 60' initiation window; pair it with pelvic-floor physical therapyHow effective? The guideline gives a judgement, not a percentage. NAMS 2020 states that low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy and ospemifene are effective treatments for moderate-to-severe GSM. It asserts effectiveness and gives no efficacy rate — so the takeaway is 'this is treatable, and enduring it is a choice', not a number⚠️ One group must take a different route: women with a history of breast cancer or an estrogen-sensitive tumour. The same NAMS 2020 statement says there are insufficient data to confirm the safety of vaginal estrogen, vaginal DHEA or ospemifene in women with breast cancer, and that GSM management should follow the woman's needs and her oncologist's recommendation. Local dosing sidesteps systemic MHT's *timing window* — it does not sidestep the contraindication. Non-hormonal vaginal moisturisers, lubricants and pelvic-floor physical therapy remain a safe first step
2 · Body composition and metabolic shift
Estrogen maintains subcutaneous (pear) fat distribution; once it departs, fat redistributes to the abdomen / viscera (shifting toward an 'apple shape')Rising visceral fat → rising insulin resistance → metabolic syndrome, type 2 diabetes, fatty liver, and cardiovascular risk all rise with it (dive to type-2-diabetes / nafld / cardiovascular)A common confusion: 'I haven't changed what I eat or how I move, but my weight went up and my waist clearly thickened' — this part is genuinely endocrine-driven, not a 'willpower problem'Meanwhile, muscle mass declines with age (sarcopenia, dive to sarcopenia); layered on rising fat = 'sarcopenic obesity,' invisible on the scale but most harmful to function
How to handle the body-composition shift (mechanism-matched levers)
Strength training (the highest-ROI single intervention): maintains muscle → maintains basal metabolism + insulin sensitivity + fall prevention, 2-3×/weekProtein 1.2-1.6 g/kg/day: the floor is the PROT-AGE expert group's recommendation for older adults who exercise (≥ 1.2 g/kg/day); the ceiling comes from Morton 2018's meta-regression, where resistance-training gains plateau around 1.6 g/kg/day and adding more buys nothing. Postmenopausal protein needs are routinely underestimated, and breakfast is especially often short (dive to sarcopenia)Watch waist, not just weight: visceral fat is the core risk, and the scale will mislead youMediterranean / DASH diet + regular aerobic work: directly offset visceral fat and metabolic risk
Marketing-trap reminder
'Menopause-specific' big-bottle supplement blends, 'natural hormone balance' / 'detox anti-aging' formulas: usually black cohosh + soy isoflavones + a vitamin mix, with weak evidence on hard bone / cardiovascular / GSM endpoints'Compounded BHRT (bioidentical hormones)' from compounding pharmacies: NAMS explicitly warns against it — standard-formulation MHT is itself bioidentical and properly regulated (detailed next)
Bottom line: postmenopause has things that self-resolve (most hot flashes) and things that don't (GSM, bone loss, the body-composition shift). Identifying and treating early the parts that don't self-resolve is this island's most practical lesson. GSM is safe and treatable — don't endure it; the body-composition shift responds to strength training + protein + waist monitoring, not supplements.
机制 · 干涩和反复尿路感染其实是同一件事
1 · 生殖泌尿综合征 (GSM) (dive 到 perimenopause 看完整治疗阶梯)GSM (旧称外阴阴道萎缩) 涵盖整个泌尿生殖系统对低雌激素的反应: 阴道干涩、灼热、性交痛、反复尿路感染、尿急尿频与潮热的关键区别: 潮热多在过渡期后几年自然减弱; GSM 不治疗就持续进展, 越晚越难治机制: 阴道、尿道上皮变薄、胶原与弹性蛋白下降、阴道 pH 升高、菌群改变被严重低治疗: 因为羞于启齿、误以为老了正常、不知道有治疗
把菌群改变那一条讲完整
雌激素让阴道表层的上皮细胞把糖原囤在细胞里。这些细胞正常脱落时, 糖原就成了乳杆菌的口粮; 乳杆菌把它发酵成乳酸, 于是阴道内一直保持在偏酸的环境, 别的菌不容易站住脚。
雌激素退场之后, 这条链一环扣一环地塌下来:
表层细胞变少、更新变慢 → 囤下的糖原变少乳杆菌没饭吃 → 数量下降乳酸变少 → pH 往上走原本被酸压住的菌 (包括从肛周过来的大肠杆菌) 站住了脚 —— 而尿道口就在旁边
所以干涩和反复尿路感染不是两个毛病, 是同一条链的两头。
这也解释了一件让很多人困惑的事: 为什么反复用抗生素治尿路感染, 每次都能治好这一次, 却挡不住下一次。抗生素杀的是已经站住脚的菌, 它没有把那块地重新变酸 —— 而下一页要说的局部雌激素, 做的正是后面这件事。
临床 · 它几乎一定治得好, 而且不受时机窗限制
核心要点 (在 perimenopause 的 GSM 场景详): 局部低剂量阴道雌激素血浆水平基本不升、风险谱与全身 MHT 完全不同, 也不受全身 MHT 那种绝经 10 年内 / 60 岁前的启动时机限制; 配合盆底物理治疗。它到底有多有效? 指南给的是判断, 不是百分比。 NAMS 2020 的原话是: 局部低剂量阴道雌激素、阴道 DHEA、全身雌激素治疗和 ospemifene 都是中-重度 GSM 的有效治疗。注意它给的是有效这个判断, 没有给任何有效率 —— 所以这一幕该记住的是它是可治的, 忍着才是在选择长期不适, 而不是记住一个百分比。
⚠️ 有一类人必须走另一条路: 有乳腺癌病史或雌激素敏感肿瘤的人。 NAMS 2020 在同一份声明里写得很清楚: 目前的数据不足以确认阴道雌激素、阴道 DHEA 或 ospemifene 在乳腺癌女性中的安全性; GSM 的处理应当结合她本人的需求和她的肿瘤科医师的建议。换句话说, 局部用药绕开的是全身 MHT 的时机窗, 不是禁忌本身 —— 这一条不能自己拍板。对这一类人, 非激素的阴道保湿剂、润滑剂和盆底物理治疗仍然是安全的第一步。
为什么局部用药能和全身用药差别这么大
药直接放在需要它的那几层组织上, 被那里的细胞就近吃掉, 真正进入血液循环的量很小。所以那些让人担心全身激素的考量 —— 血栓、乳腺、开始的年龄 —— 在这里的分量完全不同。这是把药给对了地方换来的安全边际, 不是剂量小所以效果差。
它修的到底是什么
局部雌激素让阴道上皮重新变厚、糖原重新囤起来、乳杆菌重新有饭吃、pH 重新降下去。也就是说, 它不是抹一层润滑剂把症状盖住, 而是把上一页那条链从头接回去。
这条机制顺带解释了两个常见的疑问:
为什么要用几周才见效: 上皮变厚、菌群重建都要时间, 它不是止痛药那种当场生效的东西为什么停用后会慢慢退回去: 撤掉的是维持那个状态的信号, 组织于是回到它的默认设置。这不是药没治好, 而是低雌激素这个前提一直都在
一句必须留在这里的话: 绝经后出现任何阴道出血, 属于必须立即就诊的红旗 —— 见本岛该监测什么那一幕。它和 GSM 的干涩、破皮不是一回事, 不要自己归因、自己观察。
机制 · 脂肪为什么从皮下搬到肚子里
2 · 体成分与代谢转变雌激素维持皮下 (梨形) 脂肪分布; 退场后脂肪重新分布到腹部、内脏 (向苹果形转变)内脏脂肪增加 → 胰岛素抵抗上升 → 代谢综合征、2 型糖尿病、脂肪肝、心血管风险都跟着上行 (dive 到 type-2-diabetes / nafld / cardiovascular)常见困惑: 我吃的没变、动的没变, 体重却涨了、腰围明显粗了 —— 这部分是真实的内分泌驱动, 不是意志力问题同时, 肌肉量随年龄下降 (肌少症, dive 到 sarcopenia) 与脂肪上升叠加 = 肌少性肥胖, 体重秤看不出来却最伤功能
第一条为什么会发生 (这是本岛自己讲透的一条链)
脂肪不是一个装东西的袋子, 而是一群会听指令的细胞 —— 而且不同部位的脂肪细胞, 听的指令不一样。
臀腿的皮下脂肪细胞身上雌激素受体多。雌激素在那里做两件事: 让脂肪更容易被存进去, 也让它不那么容易被动员出来。结果就是多余的能量优先往下半身走, 这就是所谓的梨形。腹腔里的内脏脂肪细胞对肾上腺素这类动员信号更敏感, 脂解更活跃, 一有风吹草动就往外倒游离脂肪酸。两者最关键的差别在排水口: 皮下脂肪释放的脂肪酸汇入全身循环, 一路被稀释; 而内脏脂肪的静脉直接汇进门静脉 —— 那是一条专门通往肝脏的管道。内脏脂肪倒出来的脂肪酸和炎症信号, 是几乎原浓度送到肝脏门口的。
雌激素退场后, 第一条里那只把脂肪往皮下引的手松开了。同样的热量盈余, 更大比例落进腹腔。于是:
内脏脂肪变多 → 门静脉里的游离脂肪酸和炎症信号变浓 → 肝细胞对胰岛素的反应变钝 → 肝脏该停的糖异生停不下来 → 空腹血糖往上抬 → 胰腺只好分泌更多胰岛素 → 更高的胰岛素又促着脂肪继续存下去 → 圈闭合。
所以你可以自己推出三件事
为什么盯腰围比盯体重秤准: 体重秤称的是全身, 而这条链上的风险几乎全部来自门静脉上游那一小块。同样的体重, 脂肪在皮下还是在内脏, 是两种完全不同的代谢处境。为什么力量训练排在补剂前面: 肌肉是全身最大的一块糖的去处, 而且它对胰岛素的敏感性在训练之后是真的会提高一阵子的。把糖引去肌肉, 等于给肝脏和胰腺分流。为什么绝经后同样的饮食更容易囤肚子: 变的不是你摄入了多少, 而是同样的能量被分配到了哪里。分配的开关换了位置 —— 这不是意志力的问题, 也不该按意志力去解决。
实操与营销陷阱
怎么应对体成分转变 (机制对位的杠杆)力量训练 (最高性价比的单一干预): 维持肌肉 → 维持基础代谢 + 胰岛素敏感性 + 跌倒预防, 2-3 次/周蛋白质 1.2-1.6 g/kg/天: 下限来自 PROT-AGE 专家组给有运动习惯的老年人的建议 (≥ 1.2 g/kg/天); 上限来自 Morton 2018 的 meta 回归 —— 配合抗阻训练时, 增益在约 1.6 g/kg/天附近趋于平台, 再往上加不再有额外回报。绝经后蛋白需求常被低估, 早餐尤其常吃不够 (dive 到 sarcopenia)关注腰围而非只看体重: 内脏脂肪是风险核心, 体重秤会骗你地中海 / DASH 饮食 + 规律有氧: 直接对冲内脏脂肪与代谢风险
为什么强调均匀分餐 (以及这一条的证据到哪一步)
先说清证据的位置: 吃够总量这件事有指南背书, 怎么分到各餐目前没有 —— PROT-AGE 自己写明, 关于摄入时机的证据尚不足以给出具体建议。所以下面这段是机制上的推论, 值得照做, 但别把它当成和总量同一级的结论。
肌肉合成不是把一天吃进去的蛋白质加起来算总账。它更像一台需要被按下才启动的机器: 一餐里的氨基酸浓度要越过一个阈值, 合成的信号才被打开, 打开之后维持几个小时就回落。晚餐吃一大块肉、早餐只有一碗粥, 等于一整天只按了一次开关 —— 总量看着够, 真正被用来盖房子的时间却很短。年纪越大, 这个阈值越高, 所以同样一份蛋白质在绝经后按不动开关的可能性更大 (这也是肌少症那一岛的核心之一)。
营销陷阱提醒
更年期、绝经专用大瓶混合补剂、天然激素平衡排毒抗衰配方: 多为黑升麻 + 大豆异黄酮 + 维生素混搭, 对骨、心血管 / GSM 的硬终点证据弱化合药店生物相同激素 (compounded BHRT): NAMS 明确警告 —— 标准制剂的 MHT 本身就是生物相同的, 且监管完善 (下一幕详)
为什么天然这个词在这里最没有信息量
你身体里的雌二醇是天然的; 药厂做出来的雌二醇和它是同一个分子, 进到细胞里找的是同一个受体, 分子本身分辨不出自己的出身。真正决定安全性的是另外四件事: 剂量多少、走什么途径进身体、你自己的风险谱是什么、有没有监管盯着这一批药。而化合药店恰恰在这四件事上最不受约束 —— 每一批的实际含量可以有出入, 也没有统一的说明书和不良反应监测。
底线: 绝经后有些事会自愈 (多数潮热), 有些不会 (GSM、骨流失、体成分转变)。把不会自愈的那部分识别出来、早处理, 是这一岛最实用的一课。GSM 安全可治、别忍; 体成分转变靠力量训练 + 蛋白 + 监测腰围, 不靠补剂。
Chapter 5
MHT · the honest post-WHI reappraisal + timing hypothesis
MHT · the honest post-WHI reappraisal + timing hypothesis
Menopausal hormone therapy (MHT / HRT) is the most misunderstood topic in menopause medicine. This island's goal: neither demonize nor oversell — give you an honest framework to bring to a conversation with your clinician. The full form selection, absolute-risk numbers, and KEEPS / ELITE RCT triangulation are detailed in the perimenopause MHT scene (dive to perimenopause); here we focus on 'how to think about this after menopause.'
The misreading of WHI 2002, and the 20-year shadow it cast (Rossouw et al. 2002)
In 2002 the WHI trial (E+P arm) stopped early + headlines read 'HRT raises breast cancer and heart attack' → US MHT prescriptions halved overnightThe ignored detail: WHI participants were on average 63, many over 10 years post-menopause, on a specific combination of conjugated equine estrogen + medroxyprogesterone acetateApplying 'results from older women long past menopause' directly to 'a 50-year-old just at menopause' is the root of the misreading
The timing hypothesis: risk and benefit depend on age and years since menopause (Manson et al. 2017, *JAMA*)
With 18 years of WHI follow-up and reanalysis stratified by age, the picture is completely different:
Start with the paper's own conclusion: over 18 years of cumulative follow-up, MHT was not associated with all-cause mortality (HR 0.99, 95% CI 0.94-1.03), cardiovascular mortality (HR 1.00, 95% CI 0.92-1.08), or cancer mortality. The authors' word is *not associated*.
So what the timing hypothesis can claim from this paper is not 'starting early lowers mortality' but something weaker and more honest: a relative difference between the younger and older strata exists (ratio of nominal HRs during intervention 0.61, 95% CI 0.43-0.87), while no single stratum's own mortality departs significantly from 1.
Started at 50-59: no significant mortality differenceStarted at 60-69: no significant differenceStarted at 70+: no significant differenceConclusion: these numbers are not a reason to take MHT for longevity, and not a reason to say it is forbidden after 60. The indication for MHT is symptoms (below); the timing window shifts the risk-benefit balance, not mortality
⚠️ One misreading worth naming: the 50-59 figure is widely quoted as HR 0.79-0.91. That is a confidence interval being passed off as the hazard ratio — and its upper bound crosses 1. Treating a CI as a point estimate deletes exactly the 'not significant' part.
The contemporary consensus of the 2022 NAMS position statement (NAMS 2022)
MHT is first-line treatment for moderate-to-severe vasomotor symptoms (hot flashes/night sweats)Fit: healthy + before 60 + within 10 years of menopause + no absolute contraindicationsAbsolute contraindications: breast-cancer history / estrogen-sensitive tumors / severe liver disease / unexplained vaginal bleeding / active VTE / stroke / MIWith a uterus: estrogen + progestogen (to protect the endometrium); without a uterus: estrogen aloneForm: transdermal (patch / gel) carries lower VTE risk than oral (avoids hepatic first-pass)
Breast-cancer risk: use absolute numbers, don't be frightened by relative risk (Chlebowski et al. 2020, *JAMA*)
5 years of E+P adds about 4-5 breast cancers per 1,000 women — '+26% relative risk' sounds scary, but the absolute increment is ~0.4-0.5%, roughly equal to the individual increments from smoking, moderate drinking, or obesityLong-term follow-up (median 20 years): in the E+P group breast-cancer incidence rose but mortality did not; in the estrogen-only group (after hysterectomy), both incidence and mortality fell
The misreading of WHI 2002, and the 20-year shadow it cast (Rossouw et al. 2002)
In 2002 the WHI trial (E+P arm) stopped early + headlines read 'HRT raises breast cancer and heart attack' → US MHT prescriptions halved overnightThe ignored detail: WHI participants were on average 63, many over 10 years post-menopause, on a specific combination of conjugated equine estrogen + medroxyprogesterone acetateApplying 'results from older women long past menopause' directly to 'a 50-year-old just at menopause' is the root of the misreading
The timing hypothesis: risk and benefit depend on age and years since menopause (Manson et al. 2017, *JAMA*)
With 18 years of WHI follow-up and reanalysis stratified by age, the picture is completely different:
Start with the paper's own conclusion: over 18 years of cumulative follow-up, MHT was not associated with all-cause mortality (HR 0.99, 95% CI 0.94-1.03), cardiovascular mortality (HR 1.00, 95% CI 0.92-1.08), or cancer mortality. The authors' word is *not associated*.
So what the timing hypothesis can claim from this paper is not 'starting early lowers mortality' but something weaker and more honest: a relative difference between the younger and older strata exists (ratio of nominal HRs during intervention 0.61, 95% CI 0.43-0.87), while no single stratum's own mortality departs significantly from 1.
Started at 50-59: no significant mortality differenceStarted at 60-69: no significant differenceStarted at 70+: no significant differenceConclusion: these numbers are not a reason to take MHT for longevity, and not a reason to say it is forbidden after 60. The indication for MHT is symptoms (below); the timing window shifts the risk-benefit balance, not mortality
⚠️ One misreading worth naming: the 50-59 figure is widely quoted as HR 0.79-0.91. That is a confidence interval being passed off as the hazard ratio — and its upper bound crosses 1. Treating a CI as a point estimate deletes exactly the 'not significant' part.
The contemporary consensus of the 2022 NAMS position statement (NAMS 2022)
MHT is first-line treatment for moderate-to-severe vasomotor symptoms (hot flashes/night sweats)Fit: healthy + before 60 + within 10 years of menopause + no absolute contraindicationsAbsolute contraindications: breast-cancer history / estrogen-sensitive tumors / severe liver disease / unexplained vaginal bleeding / active VTE / stroke / MIWith a uterus: estrogen + progestogen (to protect the endometrium); without a uterus: estrogen aloneForm: transdermal (patch / gel) carries lower VTE risk than oral (avoids hepatic first-pass)
Breast-cancer risk: use absolute numbers, don't be frightened by relative risk (Chlebowski et al. 2020, *JAMA*)
5 years of E+P adds about 4-5 breast cancers per 1,000 women — '+26% relative risk' sounds scary, but the absolute increment is ~0.4-0.5%, roughly equal to the individual increments from smoking, moderate drinking, or obesityLong-term follow-up (median 20 years): in the E+P group breast-cancer incidence rose but mortality did not; in the estrogen-only group (after hysterectomy), both incidence and mortality fell
历史 · WHI 的误读, 和它造成的二十年阴影
WHI 2002 的误读, 和它造成的二十年阴影 (Rossouw et al. 2002)2002 年 WHI 试验 (E+P 组) 中期停止 + 媒体头条HRT 增加乳癌和心梗 → 美国 MHT 处方量一夜腰斩被忽略的细节: WHI 受试者平均 63 岁, 很多人已绝经 10 年以上, 用的是马源结合雌激素 + 醋酸甲羟孕酮这一特定组合把一群离绝经很久的老年女性的结果直接套到刚绝经的 50 岁女性, 是这场误读的根源
这次误读为什么这么难纠正
试验本身并没有说错话。它在自己招募的那群人身上测到了什么, 就报告了什么。走样发生在之后的两步:
平均值被当成了每个人: 一个在特定年龄段人群里测出的平均效应, 被读成对任何女性都成立一个特定的药物组合被当成了整类治疗: 那一支用的是特定的雌激素来源和特定的孕激素, 结论却被套到所有雌激素、所有给药途径上
这两步都不需要任何人撒谎, 只需要把一个条件很具体的结论, 搬到一个条件不同的读者身上。
这也是本站反复讲机制的理由: 只记住结论的人, 在结论被更新时无从判断真假; 而理解这个结论是在谁身上、用什么药、什么时候测出来的人, 才有能力判断它适不适用于自己。
时机假说 · 它说了什么, 又没说什么
时机假说: 风险与获益取决于年龄和绝经年限 (Manson et al. 2017, *JAMA*)WHI 长达 18 年的随访 + 按年龄重新分层后, 图景完全不同:
先把这篇论文自己的结论放在最前面: 18 年累积随访下来, MHT 没有改变全因死亡率 (HR 0.99, 95% CI 0.94-1.03), 也没有改变心血管死亡率 (HR 1.00, 95% CI 0.92-1.08) 或癌症死亡率。作者的原话是未发现关联。
所以时机假说在这篇论文里能支持的, 不是早开始能降低死亡率, 而是一个更弱、也更诚实的说法: 年轻组与年长组之间的相对差异存在 (干预期两组名义 HR 之比 0.61, 95% CI 0.43-0.87), 但任何一组自己的死亡率都没有显著偏离 1。
50-59 岁开始 MHT: 死亡率未见显著差异60-69 岁开始: 未见显著差异70+ 岁开始: 未见显著差异结论: 这些数字不构成为了长寿而用 MHT 的理由, 也不构成60 岁后绝对不能用的理由。MHT 的适应症是症状(见下), 时机窗影响的是风险收益比, 不是死亡率
⚠️ 这里有一个很容易犯的读数错误, 值得单独指出: 你会在很多地方看到 50-59 岁组的数字被写成 HR 0.79-0.91。那其实是某一个 HR 的置信区间被当成了 HR 本身 —— 而那个区间的上界正好跨过 1。把 CI 当点估计, 恰好抹掉的就是不显著这条信息。
机制上为什么可能存在这样一个窗口
雌激素对血管的好处走的是内皮那条路 (见前面的心血管一幕), 而那条路需要内皮还在工作。刚绝经时, 血管壁大体还健康, 把雌激素补回来相当于把产一氧化氮的那条线重新接上; 绝经很多年之后, 管壁上往往已经有了成熟斑块, 此时加进来的雌激素面对的组织已经不同, 甚至可能影响斑块本身的稳定性。
这里必须诚实
上面这段是假说给出的解释, 不是被直接证明的因果。年龄和绝经年限无法随机分配, 所以严格意义上只检验时机的随机试验并不存在。现有支持来自两类证据, 两类都各有短板:
按年龄事后分层的再分析: 分层是事后做的, 各组人数被切小, 强度低于原始的随机比较以血管影像为终点的试验: 终点是替代指标 (比如动脉壁厚度), 不是心梗或死亡本身
所以正确的表述是: 时机假说得到了几条相互独立的证据的支持, 但它仍然是假说。
它足以支撑一条临床建议 —— 别在绝经很多年之后, 为了护心而启动全身 MHT; 但它不足以支撑一句宣传 —— 早点用就能护心。这两句话的距离, 正是证据到哪一步这件事的分量。
共识 · NAMS 立场声明, 以及两条能自己复用的推论
2022 NAMS 立场声明的当代共识 (NAMS 2022)MHT 是中-重度血管舒缩症状 (潮热盗汗) 的一线治疗适合: 健康 + 60 岁前 + 绝经 10 年内 + 无绝对禁忌绝对禁忌: 乳癌史、雌激素敏感肿瘤、严重肝病、不明阴道出血、活动性血栓、卒中、心梗有子宫: 雌激素 + 孕激素 (保护子宫内膜); 无子宫: 单用雌激素形式: 经皮 (贴、凝胶) 血栓风险低于口服 (避肝首过)
为什么有子宫就必须加孕激素
雌激素会催着子宫内膜增厚 —— 那本来是月经周期前半程为着床做的准备。正常周期里, 后半程有孕激素接手, 把内膜转成分泌期, 再随激素撤退一起脱落。只补雌激素而不加孕激素, 内膜就停在只长不落的状态里; 长期如此, 增生和癌变风险上升。所以孕激素在这里不是配套, 它是刹车。子宫已经切除的人不需要这道刹车, 单用雌激素即可。
为什么贴片和凝胶的血栓风险低于吃药
口服的药从肠道吸收后, 第一站是肝脏 —— 这叫首过效应。而肝脏正是制造凝血因子的地方: 一股高浓度的雌激素先冲过它, 会把凝血相关蛋白的产量往上推。经皮吸收绕开了这一站, 药物先进全身循环, 到达肝脏时已经被稀释。同样的血药水平, 肝脏感受到的刺激强度完全不同。
这条推论你可以自己拿去用: 凡是碰到同一个分子、不同给药途径的场景, 都先问一句 —— 它第一站去哪? 这解释的不只是 MHT 的贴片与药片, 还有前一幕说的局部阴道雌激素为什么风险谱完全不同。
数字 · 乳癌风险要用绝对数字读
乳癌风险: 用绝对数字, 别被相对风险吓住 (Chlebowski et al. 2020, *JAMA*)E+P 组 5 年使每 1000 名女性多约 4-5 例乳癌 —— 相对风险 +26% 听起来吓人, 但绝对增量约 0.4-0.5%, 大致与吸烟、中度饮酒、肥胖各自的增量相当长期随访 (中位 20 年): E+P 组乳癌发病升但死亡率未升; 单用雌激素组 (子宫切除后) 乳癌发病和死亡反而下降
相对风险为什么这么容易骗人
相对风险回答的是变成原来的几倍, 绝对风险回答的是多出来几个人。同一批数据, 底数小的时候, 前者可以听起来很惊人而后者其实很小。所以看到一个百分比, 第一个该问的问题永远是: 百分之几的什么? 底数是多少?
风险上升四分之一和每千人多四到五个说的是同一件事。两句话都没错, 但它们在脑子里唤起的画面天差地别 —— 而你要做的那个决定, 依据的应该是后面那句。
为什么单用雌激素那一组的方向不一样
这是 WHI 里常被忽略的另一半。它提示: 乳腺上发生的事更可能与孕激素成分有关, 而不是雌激素本身。同时它也提醒我们, MHT 不是一种药, 而是一类方案 —— 用哪种雌激素、配不配孕激素、配哪一种、走什么途径, 结论都可能不一样。
所以下次听到激素治疗致癌这句话, 值得追问三件事: 说的是哪一种组合? 在什么年龄开始? 增加的是发病还是死亡? 三个问题里少问一个, 得到的答案就可能与你的处境无关。
How to think about MHT after menopause (the honest conclusion)
How to think about MHT after menopause (the honest conclusion)Bothersome moderate-to-severe hot flashes + within the timing window + no contraindications → MHT is first-line and worth a serious discussionStarting systemic MHT years after menopause purely for 'anti-aging / heart protection / osteoporosis prevention' → not recommended; the timing window has passed and the risk balance differsContraindications, or you'd rather not use hormones → non-hormonal options do work, and they have a guideline of their own: the NAMS 2023 nonhormone therapy position statement (a separate document from the hormone statement above) recommends, for vasomotor symptoms, SSRIs/SNRIs (e.g. paroxetine, venlafaxine), gabapentin, fezolinetant (a new non-hormonal drug approved in 2023; phase-3 evidence in SKYLIGHT 2), plus cognitive-behavioral therapy and clinical hypnosis (all Level I); oxybutynin is Levels I-II; clonidine is not recommended. For bone: see osteoporosisFor GSM → local vaginal estrogen is not bound by the timing window — but note it is not an exception to the contraindications: with a history of breast cancer the decision belongs with your oncologist (see this island's GSM scene)POI (menopause before 40) → a different matter: hormone replacement is strongly recommended until the natural menopause age (~51); not replacing equals entering low-estrogen aging prematurely
Bottom line: MHT is not a 'should I or shouldn't I' yes/no question — it is a 'individualized weighing under your age, years since menopause, symptoms, and risk profile' decision. This site does not replace a physician — it helps you understand the timing hypothesis and the absolute numbers so you can bring judgment to a shared decision.
nams-2023-nonhormone-positionlederman-2023-skylight-2
Chapter 6
What to actually monitor + atlas loop
What to actually monitor + atlas loop
Let's distill the system shifts above into an actionable monitoring checklist — the core of postmenopausal health management is not taking a miracle pill, but 'watching the right metrics + pulling the right levers.'
What to monitor regularly (confirm your individual frequency with a clinician)
Blood pressure: the core modifiable item for the rising cardiovascular risk — measure regularly (dive to hypertension)Lipids: monitor LDL / HDL / triglycerides; lipids often worsen across the transition — discuss with your clinician whether a statin is warranted (dive to cardiovascular)Glucose / HbA1c: rising visceral fat → insulin resistance → watch glucose metabolism (dive to type-2-diabetes)Bone density DXA: routine from 65; earlier for postmenopausal women with risk factors (USPSTF 2025; detailed in the bone scene above)Vitamin D status: keep it sufficient to support calcium absorption and bone health (dive to vitamin-d)Waist circumference / body composition: reflects visceral fat and metabolic risk better than the scaleRoutine screening: breast, cervical, etc. per guidelines; any postmenopausal vaginal bleeding requires immediate evaluation (a genuine red flag — don't delay)
Levers to pull long-term (mechanism-matched, ranked by ROI)
Strength training 2-3×/week — simultaneously protects bone, muscle, insulin sensitivity, and fall risk (dive to sarcopenia)Regular aerobic + Mediterranean / DASH diet — offsets cardiovascular and metabolic riskCalcium (food first) + vitamin D — the nutritional foundation for bone, not high-dose supplementsProtein 1.2-1.6 g/kg — maintains muscle and bone matrix (floor: PROT-AGE for older adults who exercise; ceiling: Morton 2018's training-response plateau. Spread it across meals if you can, but the distribution evidence is weaker than the total)Quit smoking, limit alcohol, regular sleep — three high-return basics (sleep-architecture changes, dive to sleep-architecture)
What to monitor regularly (confirm your individual frequency with a clinician)
Blood pressure: the core modifiable item for the rising cardiovascular risk — measure regularly (dive to hypertension)Lipids: monitor LDL / HDL / triglycerides; lipids often worsen across the transition — discuss with your clinician whether a statin is warranted (dive to cardiovascular)Glucose / HbA1c: rising visceral fat → insulin resistance → watch glucose metabolism (dive to type-2-diabetes)Bone density DXA: routine from 65; earlier for postmenopausal women with risk factors (USPSTF 2025; detailed in the bone scene above)Vitamin D status: keep it sufficient to support calcium absorption and bone health (dive to vitamin-d)Waist circumference / body composition: reflects visceral fat and metabolic risk better than the scaleRoutine screening: breast, cervical, etc. per guidelines; any postmenopausal vaginal bleeding requires immediate evaluation (a genuine red flag — don't delay)
Levers to pull long-term (mechanism-matched, ranked by ROI)
Strength training 2-3×/week — simultaneously protects bone, muscle, insulin sensitivity, and fall risk (dive to sarcopenia)Regular aerobic + Mediterranean / DASH diet — offsets cardiovascular and metabolic riskCalcium (food first) + vitamin D — the nutritional foundation for bone, not high-dose supplementsProtein 1.2-1.6 g/kg — maintains muscle and bone matrix (floor: PROT-AGE for older adults who exercise; ceiling: Morton 2018's training-response plateau. Spread it across meals if you can, but the distribution evidence is weaker than the total)Quit smoking, limit alcohol, regular sleep — three high-return basics (sleep-architecture changes, dive to sleep-architecture)
杠杆 · 为什么是这几个, 而且为什么力量训练排第一
该长期拉的杠杆 (机制对位, 按性价比排序)力量训练 2-3 次/周 — 同时护骨、护肌、改善胰岛素敏感性、防跌倒 (dive 到 sarcopenia)规律有氧 + 地中海 / DASH 饮食 — 对冲心血管与代谢风险钙 (食物优先) + 维生素 D — 骨的营养基础, 不靠大剂量补剂蛋白质 1.2-1.6 g/kg — 维持肌肉与骨基质 (下限 PROT-AGE 给有运动习惯的老年人, 上限 Morton 2018 的训练回报平台; 尽量分到各餐, 但分餐的证据弱于总量)戒烟、限酒、规律睡眠 — 三件回报极高的基础 (睡眠结构变化 dive 到 sleep-architecture)
为什么力量训练排第一, 而不是某种补剂
回头看这一岛开头那条主线: 雌激素撤退, 松开了骨、血管、体温、脂肪分布几只手。力量训练一次动作, 同时压中其中三条:
骨: 肌肉拉扯骨头产生的形变, 是骨细胞判断要不要加固的主要输入 —— 这是骨听得懂的唯一语言代谢: 肌肉是全身最大的糖的去处, 训练之后它对胰岛素的敏感性会真实提高一阵子, 等于替肝脏和胰腺分流功能: 肌力和平衡决定的是会不会摔, 而骨密度决定的只是摔了会不会断。两件事都要管, 但前一件最常被忘掉
没有任何一种补剂能一次覆盖这三条。这不是说补剂无用, 而是顺序问题: 补剂送来的是原料, 训练发出的是要不要动用这些原料的指令。原料堆到位而指令不发, 骨和肌肉不会自己变强 —— 这也是为什么单靠补钙很难换来骨密度。
一个最常被跳过的杠杆: 睡眠
绝经后睡眠常变浅、变碎, 而睡不够会同时做三件坏事: 推高第二天的胰岛素抵抗、放大对疼痛与不适的感知、让本来能睡过去的潮热把人吵醒。它和体成分、情绪、症状是互相咬住的, 不是睡不好而已 (dive 到 sleep-architecture / insomnia)。
怎么用这份清单: 别一次全上。挑一个你当下最缺的杠杆, 让它稳定成为习惯, 再加下一个 —— 这一岛讲的是余生三分之一的时间, 拼的从来不是三个月内做了多少。
Atlas loop — postmenopause is where many systems converge
Atlas loop — postmenopause is where many systems convergeperimenopause — the transition story (this island's 'prequel': hot flashes / KNDy / diagnosis / the GSM treatment ladder / the full MHT numbers)osteoporosis — T-scores, FRAX, the drug ladder (the 'deep dive' for this island's bone scene)cardiovascular — endothelium, lipids, atherosclerosis mechanismhypertension — blood-pressure managementtype-2-diabetes / nafld — the downstream metabolic risks of rising visceral fatsarcopenia — muscle loss / sarcopenic obesity and strength trainingsleep-architecture / insomnia — sleep-structure changes and insomnia managementchronic-stress — stress and the hormonal transition amplifying each other
A suggested atlas learning path for postmenopausal women
1. This island — understand the 'durable low-estrogen state' and the system shifts
2. osteoporosis — the bone-loss window and whether you need medication
3. sarcopenia — strength training + protein baseline
4. cardiovascular + hypertension — cardiovascular risk monitoring
5. perimenopause — if you still have hot flashes / are considering MHT, see the full decision
6. sleep-architecture — if your sleep has become lighter / fragmented
Bottom line: postmenopause is a life stage you can actively manage, not a passive wait for decline. Estrogen's departure raises the risk in several systems, but each has clear monitoring metrics and mechanism-matched levers — watch the right metrics, pull the right levers, and when MHT is appropriate, decide together with your clinician within the timing window. Know the what and the why, and you neither panic nor get harvested by 'anti-aging miracles.' This site does not replace a physician; any persistent or abnormal symptom warrants medical evaluation.
References · 13
- Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. The Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. 10.1210/jc.2011-3362
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. 10.1097/GME.0000000000002028
- Greendale, G. A., Sowers, M., Han, W., Huang, M. H., Finkelstein, J. S., Crandall, C. J., Lee, J. S., & Karlamangla, A. S. (2012). Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of Bone and Mineral Research, 27(1), 111-118. 10.1002/jbmr.534
- US Preventive Services Task Force; Nicholson, W. K., Silverstein, M., Wong, J. B., et al. (2025). Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA, 333(6), 498-508. 10.1001/jama.2024.27154
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 25(10), 2359-2381. 10.1007/s00198-014-2794-2
- El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., & Allison, M. A. (2020). Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation, 142(25), e506-e532. 10.1161/CIR.0000000000000912
- The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. (2020). Menopause, 27(9), 976-992. 10.1097/GME.0000000000001609
- Portman, D. J., & Gass, M. L. S. (2014). Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from ISSWSH and NAMS. Menopause, 21(10), 1063-1068. 10.1097/GME.0000000000000329
- Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., et al. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: PROT-AGE Study Group. JAMDA, 14(8), 542-559. 10.1016/j.jamda.2013.05.021
- Morton, R. W., et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine, 52(6), 376–384. 10.1136/bjsports-2017-097608
- Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. 10.1001/jama.288.3.321
- Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA, 318(10), 927-938. 10.1001/jama.2017.11217
- Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA, 324(4), 369-380. 10.1001/jama.2020.9482